Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge.
about
Pathogenesis of human immunodeficiency virus infectionComparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIVCharacteristics of a pathogenic molecular clone of an end-stage serum-derived variant of simian immunodeficiency virus (SIV(F359)).Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies.A combination DNA and attenuated simian immunodeficiency virus vaccine strategy provides enhanced protection from simian/human immunodeficiency virus-induced disease.Postexposure immunoprophylaxis of primary isolates by an antibody to HIV receptor complex.HIV-1 Gag p17 presented as virus-like particles on the E2 scaffold from Geobacillus stearothermophilus induces sustained humoral and cellular immune responses in the absence of IFNγ production by CD4+ T cells.Macaques immunized with HLA-DR are protected from challenge with simian immunodeficiency virus.Vaccine-induced virus-neutralizing antibodies and cytotoxic T cells do not protect macaques from experimental infection with simian immunodeficiency virus SIVmac32H (J5)Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara.The Trojan exosome hypothesisLessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones.Incomplete protection, but suppression of virus burden, elicited by subunit simian immunodeficiency virus vaccinesImmunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques.Studies of the conformation-dependent neutralizing epitopes of simian immunodeficiency virus envelope proteinVaccine-induced neutralizing antibodies directed in part to the simian immunodeficiency virus (SIV) V2 domain were unable to protect rhesus monkeys from SIV experimental challenge.Immune response of rhesus macaques to recombinant simian immunodeficiency virus gp130 does not protect from challenge infection.Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques.Replication and persistence of simian immunodeficiency virus variants after passage in macaque lymphocytes and established human cell lines.Efficacy of inactivated whole HIV-2 vaccines with various adjuvants in cynomolgus monkeys.Immunization with whole inactivated vaccine protects from infection by SIV grown in human but not macaque cells.SIVmac vaccine studies using whole inactivated virus antigen sequentially depleted of viral proteins.
P2860
Q24634681-AADC80D3-5D7C-478A-BFD3-21300F52AB32Q33800033-B7F492BA-D5DE-4DD7-B0C0-FDCEF6B2614BQ33845764-CED65133-8C78-4F02-BA18-2447FB6337F4Q34150125-6150E613-9668-4F61-B8FB-6076D773516DQ34228507-8E7BC0DE-5666-4EB5-9DFF-0C7261FB8F6BQ35621250-A2F26CC1-5665-4FAD-8339-43BB34C35FB7Q35745815-241A2239-BFB7-491B-B114-5B7DEABBE2BCQ35839114-4113DA45-A3BA-4817-83D7-4BF382B3E5F8Q35848231-19737EC4-346F-4BA4-A60A-8303B49A98D3Q35861490-CB6EEE1D-A9FF-4E4E-8E71-8A2A45388482Q35976953-224F4B5E-B486-4B9E-B54C-DCFFDB9E11F5Q36009232-56171488-C328-4EBF-BB80-E4A0A14DE232Q36630114-B01A12AE-5480-4B3C-AFB2-2B8F7A069745Q36631918-09F826C8-3AF3-49E9-AA86-7CE22F1B5F0FQ36632605-B4327089-B285-46EF-892F-3425D1B527FAQ36636293-71653C3A-F471-4D52-8162-9A133FE05E6AQ36640342-7FC4B352-B539-43BE-98A0-DA3E08FFD369Q37743813-232A3913-8162-4BCC-B9AE-085CE637BA99Q40044609-44C85DFE-517F-4926-B59F-5B9C0E6B5D69Q41491959-FF49DFD4-75DD-474E-A5B8-32B5FA3D15CFQ41491967-C48BF8E8-43EE-42C5-A03D-48A3BC088EA7Q45751941-E58AF7DF-6087-4F26-B322-DB4D0B51AEF7
P2860
Inactivated whole-virus vaccine derived from a proviral DNA clone of simian immunodeficiency virus induces high levels of neutralizing antibodies and confers protection against heterologous challenge.
description
1992 nî lūn-bûn
@nan
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
1992年论文
@zh
1992年论文
@zh-cn
name
Inactivated whole-virus vaccin ...... gainst heterologous challenge.
@en
type
label
Inactivated whole-virus vaccin ...... gainst heterologous challenge.
@en
prefLabel
Inactivated whole-virus vaccin ...... gainst heterologous challenge.
@en
P2093
P2860
P356
P1476
Inactivated whole-virus vaccin ...... gainst heterologous challenge.
@en
P2093
N L Haigwood
P R Johnson
S Goldstein
W T London
P2860
P304
P356
10.1073/PNAS.89.6.2175
P407
P577
1992-03-01T00:00:00Z